Botox injection into the bladder at the time of prostate surgery to reduce overactive bladder symptoms.
Official title: Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms
Run by Benaroya Research Institute · NCT07377929 · Data updated 2026-11-12
This test looks at whether a Botox shot into the bladder given during TURP or Aquablation helps men with BPH who have overactive bladder symptoms feel better after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 20 (estimated) |
| Sponsor | Benaroya Research Institute Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Status | Recruiting |
| Started | January 19, 2026 |
| Main results expected | May 1, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | January 30, 2026 |
| Trial ID | NCT07377929 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 18 or older who are scheduled for TURP or Aquablation, have overactive bladder symptoms, can provide informed consent, and can complete English-language questionnaires are the ideal candidates.
✕Probably not a fit
Patients without overactive bladder symptoms, those who received bladder Botox within the last 12 months, or those unable to complete English questionnaires are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Men scheduled for transurethral resection of the prostate (TURP) or transurethral waterjet ablation (Aquablation) who have baseline overactive bladder symptoms receive intradetrusor onabotulinumtoxinA (Botox) at the time of their procedure. Outcomes are tracked using patient questionnaires about urinary frequency, urgency, and recovery in the immediate postoperative period and at follow-up. The study excludes non-English speakers and anyone who received bladder Botox within the prior 12 months. This is an observational registry-style protocol collecting real-world symptom data around routine clinical care rather than assigning treatments by randomization.
Why it matters
Potential benefit: If successful, giving Botox at the time of prostate surgery could reduce early postoperative urgency and frequency and speed symptom recovery.
How similar studies have gone: Botox is an FDA-approved and effective treatment for overactive bladder, but using it at the time of prostate surgery is relatively novel with limited direct evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male \>= 18 years of age and being scheduled to undergo TURP or Aquablation and Botox procedure. 2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: 3. Non-English speaking 4. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 5. History of receiving Botox in the bladder, within the previous 12 months.
Where it's running
-
Virginia Mason Franciscan Health
Seattle, Washington, United States Recruiting
Study contacts
- Study coordinator: Thomas W. Fuller, MD
- Email: will.fuller@commonspirit.org
- Phone: 206-223-6772
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Silodosin for urinary symptoms in women with MS
This study tests whether silodosin helps relieve lower urinary tract symptoms in women with multiple sclerosis, compared with a placebo.
-
Low-energy shock wave treatment for overactive bladder in women with metabolic syndrome
This trial tests whether low-energy extracorporeal shock wave therapy (LiESWT) can reduce urgency, daytime frequency, and nighttime urination in women who have metabolic syndrome.
-
Comparing bipolar enucleation versus transurethral resection for enlarged prostate outcomes and patient experience
This trial will test whether bipolar enucleation or standard transurethral resection gives better urinary symptoms, patient experience, and value for men with enlarged prostates who are referred for surgery.
-
Combination finasteride plus raloxifene therapy with epigenetic biomarker testing for benign prostate enlargement
This project will test whether adding raloxifene to finasteride and using epigenetic biomarker tests helps men with benign prostate enlargement who are candidates for finasteride.
-
Normal bladder and urethral pressure ranges measured with e-Sense catheters
This project will test e-Sense catheters to define normal urodynamic pressure values in adults referred for urodynamic testing, with enrollment focused on people aged 20–35 (women nulliparous) and those over 50 (women with at least one vaginal birth).
-
Adaptive radiotherapy for localized prostate cancer
This study is testing a new type of radiation therapy for men with localized prostate cancer who have urinary problems to see if it can safely treat their cancer without causing too many side effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.